News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Possible New Lease On Life For Two Heart Drugs From Merck & Co., Inc. (MRK) And Johnson & Johnson (JNJ)


12/18/2013 6:56:01 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Early next year an FDA panel will review a new drug from Merck and a new indication for Xarelto (rivaroxaban), Johnson & Johnson's JNJ -0.78% highly successful new oral anticoagulant. Both drugs have had a rocky road getting to this stage and their success is by no means assured, but the announcement of the meeting of the FDA’s Cardiovascular and Renal Drugs Advisory Committee suggests that the companies have made progress resolving earlier problems.

Hey, check out all the research scientist jobs. Post your resume today!

Read at Forbes

comments powered by Disqus
Forbes
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES